Results reveal mechanism driving high blood pressure and point toward more precise therapies targeting communication between fat and blood vessels.

Following the closing, the Emeryville and Berkeley, CA, biologics manufacturing facilities will be transferred to Zydus.

Cell therapy manufacturing is patient-specific and time-sensitive, making regional production capacity increasingly important.

In this GEN webinar, experts from Perceptive Imaging and Flywheel explore how imaging data access issues slow decision-making and increase risks for both biopharma and CROs.

The images showed that nearly all the antibodies bind to a single domain of the receptor, providing a viable target for novel therapeutics.

The landscape of next-generation sequencing (NGS) continues to be defined by astonishing technological progress. We continue ...

In this GEN webinar, Guilherme Yamamoto, MD, PhD, and Sevana Yaghoubian will present a novel whole-exome assay for detecting high-confidence variants across multiple applications.

A profound transformation is taking place in therapeutic discovery, development, and delivery.2026 will be a pivotal year for ...

SHERLOCK, a rapid CRISPR-based diagnostic, detects Candida auris and antifungal resistance mutations in patient samples in under an hour.

Silicon Valley microprocessing giant Nvidia and pharma powerhouse Eli Lilly announced a five-year, $1 billion partnership to create a “Co-Innovation AI Lab” designed to address key challenges in AI ...

Benefits seen from embracing platform technologies, combined with the role such systems played during the pandemic, are key dynamics.

Illumina unveiled the Billion Cell Atlas, a large‑scale genetic perturbation dataset built with pharma partners to advance AI‑powered drug discovery, target validation, and disease biology.